The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo.

ABSTRACT

The RXR serves as a heterodimer partner for the PPARgamma and the dimer is a molecular target for insulin sensitizers such as the thiazolidinediones. Ligands for either receptor can activate PPAR-dependent pathways via PPAR response elements. Unlike PPARgamma agonists, however, RXR agonists like LG100268 are promiscuous and activate multiple RXR heterodimers. Here, we demonstrate that LG100754, a RXRRXR antagonist and RXRPPARalpha agonist, also functions as a RXRPPARgamma agonist. It does not activate other LG100268 responsive heterodimers like RXRliver X receptoralpha, RXRliver X receptorbeta, RXRbile acid receptor/farnesoid X receptor and RXRnerve growth factor induced gene B. This unique RXR ligand triggers cellular RXRPPARgamma-dependent pathways including adipocyte differentiation and inhibition of TNFalpha-mediated hypophosphorylation of the insulin receptor, but does not activate key farnesoid X receptor and liver X receptor target genes. Also, LG100754 treatment of db/db animals leads to an improvement in insulin resistance in vivo. Interestingly, activation of RXRPPARgamma by LG100268 and LG100754 occurs through different mechanisms. Therefore, LG100754 represents a novel class of insulin sensitizers that functions through RXR but exhibits greater heterodimer selectivity compared with LG100268. These results establish an approach to the design of novel RXR-based insulin sensitizers with greater specificity.